Phase 2 Results of CFTR Potentiator Show Evidence of Comparable Efficacy to Kalydeco
Dec 22, 2016 09:30 am | Daniela Semedo, PhD
Galapagos NV recently reported positive topline results from SAPHIRA 1, a Phase 2 clinical trial assessing the company’s potentiator molecule, GLPG1837, in patients with cystic fibrosis (CF) who have the G551D mutation. Data showed results comparable to an approved CF treatment, the company announced. SAPHIRA 1 (NCT02707562) was an open-label, four-week clinical trial testing three successive doses of […]
The post Phase 2 Results of CFTR Potentiator Show Evidence of Comparable Efficacy to Kalydeco appeared first on Cystic Fibrosis News Today.